Clinical Trial Update: Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LYT-100 (deupirfenidone) versus pirfenidone for Idiopathic Pulmonary Fibrosis; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• LYT-100
• Pirfenidone (Esbriet) (pirfenidone)

Snippet

Sponsor: PureTech | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Status: NOT_YET_RECRUITING